๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lupus Nephritis
Clinical trial register · China

Lupus Nephritis Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Guangzhou 7 Nanjing 6 Wuhan 6 Shenzhen 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Guangzhou7 Nanjing6 Wuhan6 Shenzhen4
All 33 locations
Target enrolment
to

Lupus Nephritis trials in China

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
By invitation
CHT105 for the Treatment of Refractory Lupus Nephritis
NCT07517536Systemic Lupus Erythematosus, Lupus Nephritis
DrugCHT105
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
14
Nanjing
2026-04-22
Not yet open
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
NCT07393451Lupus Nephritis
Simcere Pharmaceutical Co., Ltd
Phase 2
60
Beijing
2026-03-31
Recruiting
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
Beijing Biotech
Phase 1/2
24
Shenzhen
2026-03-02
Recruiting
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
NCT07109986Systemic Lupus Erythematosus, Lupus Nephritis
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
21
Nanjing
2025-10-27
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
NCT06904729Lupus Nephritis
Guangzhou Women and Children's Medical Center
Phase 3
50
Guangzhou
2025-05-01
Recruiting
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
NCT06785519Lupus Nephritis
He Huang
Phase EARLY_PHASE1
9
Hangzhou
2025-01-31
Recruiting
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
NCT06350110Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Essen Biotech
Phase 1/2
75
Beijing
2024-07-10
Recruiting
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
NCT06497361Lupus Nephritis, IgG4-related Disease
Tongji Hospital
Phase EARLY_PHASE1
30
Wuhan
2024-07
Recruiting
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
NCT06497387Lupus Nephritis, IgG4-related Disease
Tongji Hospital
Phase EARLY_PHASE1
30
Wuhan
2024-07
Recruiting
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
NCT06285279Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases
Nanjing University School of Medicine
Phase 1
24
Nanjing
2024-03-04
Recruiting
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
NCT06277427Lupus Nephritis, ANCA Associated Vasculitis
Lingli Dong
Not applicable
24
Wuhan
2024-02-05
Recruiting
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
NCT06406205Lupus Nephritis
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174Lupus Nephritis
Chinese SLE Treatment And Research Group
Observational
100
Beijing
2023-12-05
Recruiting
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
NCT06058078Lupus Nephritis
Jiangsu Renocell Biotech Company
Phase 2
60
Nanjing
2023-08-17
Recruiting
A Study of Telitacicept in Lupus Nephritis
NCT05680480Lupus Nephritis
RemeGen Co., Ltd.
Phase 2
120
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Liuzhou, Guiyang, Baoding
2023-04-17
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Nanning, Wuhan, Shenyang, Yinchuan, Beijing, Shenzhen
2022-08-10
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Active, closed
Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
NCT07044115Lupus Nephritis
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
41
Beijing
2021-11-26
Recruiting
High Quality Evidence of Chinese Lupus Nephritis (HELP)
NCT03001973Lupus Nephritis
Sun Yat-sen University
Observational
5,000
Guangzhou
2013-11
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/lupus-nephritis

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Lupus Nephritis.

How many Lupus Nephritis trials are recruiting in China?

16 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lupus Nephritis), 22 studies
PhaseStudiesRecruitingShare
Phase 36327.3%
Phase 24318.2%
Phase 1/23213.6%
Phase EARLY_PHASE13313.6%
Not applicable219.1%
Observational229.1%
Phase 1229.1%

Most active sponsors

Lead sponsors with the most studies (Lupus Nephritis)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals32
Tongji Hospital22
AstraZeneca10
Beijing Biotech11
Beijing Mabworks Biotech Co., Ltd.10
Chinese SLE Treatment And Research Group11
Essen Biotech11
Guangzhou Women and Children's Medical Center11
He Huang11
Jiangsu Renocell Biotech Company11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.